Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.51 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 3/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9523155 | 0.91 | TAS1R3 (0.49) | MTNR1AMTNR1BPPARD | |
| SCHEMBL27989609 | 0.89 | SRD5A1 (0.50) | MTNR1AMTNR1BPPARDSRD5A1CYP19A1 | |
| SCHEMBL1844946 | 0.88 | PPARD (0.52) | MTNR1AMTNR1BPPARDSRD5A1CYP19A1 | |
| SCHEMBL19838588 | 0.88 | MTNR1A (0.59) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL19469507 | 0.86 | MTNR1A (0.50) | MTNR1AMTNR1BPPARDSRD5A1CYP19A1 | |
| SCHEMBL19002298 | 0.84 | PPARD (0.46) | MTNR1AMTNR1BPPARDSRD5A1CYP19A1 | |
| SCHEMBL19002833 | 0.84 | MTNR1A (0.47) | MTNR1AMTNR1BPPARDSRD5A1CYP19A1 | |
| SCHEMBL1844672 | 0.79 | SIRT1 (0.53) | PPARDSLC6A9 | |
| SCHEMBL31366772 | 0.78 | ACHE (0.52) | MTNR1AMTNR1BCYP19A1NQO2 | |
| SCHEMBL1877585 | 0.78 | ACHE (0.52) | MTNR1AMTNR1BCYP19A1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | MTNR1A 1704/4885MTNR1B 1599/4885PPARD 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.